Phase 1 clinical trials for the treatment of HCV using a microRNA-targeted drug, SPC3649. Study published in Nature that shows LNA-based drugs targeting microRNAs capacity in non-human primates. 2009: Establishment of branch in San Diego, California, United States of America. Formed collaboration with Shire to develop RNA-based medicines for the treatment of rare genetic disorders. Advanced the 4955 into drug development, which is a compound that targets Apolipoprotein B and could decrease and manage high cholesterol into drug development. Publication in Science showing how the breakthrough microRNA-targeted therapy SPC3649 is a promising new treatment for Hepatitis C. Wyeth Pharmaceuticals and Santaris Pharma announce their partnership to develop RNA-targeted medicines. 2010: Santaris Pharma A/S and miRagen Therapeutics form an alliance to develop microRNA-targeted medicines for treatment of cardiovascular disease. Advanced SPC5001, which targets PCSK9, into drug development for the treatment of high cholesterol. Received the Red Herring Top 100 Europe Award. 2011: Obtained license from Mass General Hospital for intellectual property related to miR-33 regulations for cardiovascular disorder treatment. Expanded collaborations with Pfizer Inc. directed on development of RNA-targeted medicines. Santaris made medical history with their advancement of miravirsen to Phase II trials, which is the first microRNA-targeted drug to enter clinical trials, and aims to treat patients infected with Hepatitis C. 2013: Santaris Pharma A/S and Bristol-Myers Squibb form an alliance to develop lead candidates against a limited number of targets 2013: Santaris Pharma A/S and RaNa form an alliance to develop lead candidates against <10 of RaNA’s proprietary RNA targets for the treatment of human diseases 2014: Santaris Pharma A/S was acquired by Roche and renamed the Roche Innovation Center Copenhagen. Awards 2008: Fierce 15 by Fierce Biotechnology 2010: Red Herring Top 100 Europe Award 2011: Finalist for 2011 Scrip Awards in the "Clinical Research Team of the Year" category. Corporate structure Executives J. Donald deBethizy – President & Chief Executive Officer Henrik Stage, MS. – Chief Financial Officer & EVP Corporate Development Henrik Ørum, MSc PhD – VP & Chief Scientific Officer Michael R. Hodges, MD – VP & Chief Medical Officer Troels Koch, PhD – VP & Chief Technology Officer Bo Rode Hansen, PhD – VP, Alliance Management & Partnered Drug Discovery Litigation Santaris Pharma A/S vs. Exiqon A/S Exiqon brought Santaris to court to obtain more rights of LNA technology in 2010. On Friday, October 7, 2011, all the allegations initiated by Exiqon against Santaris were